Radioligand binding assay of epidermal growth factor receptor: causes of variability and standardization of the assay.
Although experimental evidence indicates a probable role of epidermal growth factor receptor (EGFr) in clinical oncology, no standardized method for its determination has been yet described, and discrepant results have been reported in clinical studies. In standardizing a radioligand binding assay for EGFr, we evaluated the causes of variability in each step of the assay. Entrapment of EGFr in the nuclear fraction and contamination of the crude membrane fraction by cytosol protein were eliminated through preliminary purification steps. Both Scatchard and Rosenthal analysis of the saturation reaction of the membrane fraction with a wide range of concentrations of 125I-labeled EGF revealed a double class of binding sites. Study of the saturation reaction showed a partial exchange of 125I-labeled EGF with endogenous EGF within 20 h. The present method--incubation of partly purified membrane fraction with 125I-labeled EGF, 0.5 nmol/L, with and without 100-fold excess of cold EGF, for 20 h at 26 degrees C, followed by centrifugation at 5000 x g for 30 min to separate membrane-bound 125I-labeled EGF--shows good sensitivity, precision, and accuracy; is reasonably simple; and may be suitable for routine clinical use.
Dittadi
R
R
Center for the Study of Biological Markers of Malignancy, Regional General Hospital, Venice, Italy.
Gion
M
M
Brazzale
A
A
Bruscagnin
G
G
D000704:Analysis of Variance; D002462:Cell Membrane / Q000032:analysis; D066246:ErbB Receptors / Q000032:analysis* / Q000592:standards; D005260:Female; D006801:Humans; D010920:Placenta / Q000032:analysis; D011869:Radioligand Assay / Q000592:standards
D066246:ErbB Receptors